Please assess the completion status of the following clinical trial:

Trial Title: Test-and-treat for Influenza in Homeless Shelters

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Resident for 1 or more days at a participating shelter~* ≥2 ARI symptoms or acute cough alone~* Willing to take study medication~* Willing to comply with all study procedures, including weekly surveillance and repeat nasal swab at day 2/3 and day 5/6/7 post-treatment~* Able to provide written, informed consent and/or assent~Exclusion Criteria:~* Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration~* Inability to consent and/or comply with study protocol~* Individuals who have received oseltamivir or baloxavir within past 7 days for treatment of influenza~* Individuals with known hypersensitivity to baloxavir marboxil or oseltamivir~* Individuals with chronic kidney disease

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard influenza surveillance (Type: NO_INTERVENTION): Subjects exhibiting ≥ 2 ARI symptoms or new or worsening cough in the last 7 days at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab for RT-PCR testing.
- Point-of-care molecular testing and treatment of influenza (Type: ACTIVE_COMPARATOR): Subjects exhibiting ≥ 2 ARI symptoms, or new or worsening cough, in the last 48 hrs at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab to be tested on-site with a molecular assay (Abbott ID NOW™ Influenza A \& B (Chicago, IL)) and receive an antiviral if tested positive (XOFLUZA™ or Tamiflu®) .

Based on this trial design, predict the completion outcome and termination type (if applicable).